Michael Carducci, MD
Enriched profileAEGON Professor of Prostate Cancer Research; Vice Chair, Solid Tumor Oncology · Johns Hopkins University School of Medicine
Michael Carducci is AEGON Professor of Prostate Cancer Research; Vice Chair, Solid Tumor Oncology at Johns Hopkins University School of Medicine. OpenAlex indexes 1,096 publications with 56,123 citations (h-index 104); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Michael Carducci as a Highly Cited Researcher (Cross-Field, 2018).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Michael Carducci, MD, is AEGON Professor of Prostate Cancer Research at Johns Hopkins University School of Medicine, Department of Oncology / Sidney Kimmel Comprehensive Cancer Center. The public record shows 1,096 publications with 56,123 citations (h-index 104), centered on Prostate Cancer, Lymphoma, Kidney Cancer / RCC. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 6 companies, 9 NIH-funded awards (1996–2026).
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Prostate Cancer
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Sponsor: National Cancer Institute (NCI)
- Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20254 payments
- Astellas Pharma US IncProgram year20246 payments
- AstraZeneca UK LimitedProgram year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.5%Cytochrome P450 17A1 Inhibitor50.4%Abiraterone Acetate100%Part D≥29 patientsAndrogen Receptor Inhibitor17.5%Xtandi59%Bicalutamide41%Part D<11 patientsMetabolism & gastrointestinal
21.5%Corticosteroid21.5%Prednisone100%Part D≥38 patientsNervous system
3.3%Opioid Agonist3.3%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
9 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
Johns Hopkins University
FY2026$1,854,447UM1CA186691
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal of clinical oncology
Guideline2026 - National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal of clinical oncology
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-carducci-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Michael-A-Carducci-39059379
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
cancer-matters.blogs.hopkinsmedicine.org/2018/12/19/three-minutes-with-oncologist-michael-carducci
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer-matters.blogs.hopkinsmedicine.org ↗ - Other
onclive.com/authors/michael-a-carducci-md-facp-sidney-kimmel-comprehensive-cancer-center-of-johns-hopkins-hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Other
urotoday.com/video-lectures/advanced-prostate-cancer/video/4953-consensus-recommendations-for-parp-inhibitor-use-in-metastatic-prostate-cancer-michael-carducci.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- Associate Cancer Center Director for Clinical Research
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Regional Oncology Research Director
Kimmel Cancer Center National Capital Region
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urology.jhu.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →professorships.jhu.edu ↗
Secondary affiliations
appointments beyond the home institution- Professor of Urology
James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urology.jhu.edu ↗
Media & interviews
press, podcasts and appearances- "Three Minutes with Oncologist Michael Carducci" - video interview
Cancer Matters (Johns Hopkins Medicine blog), Dec 19
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer-matters.blogs.hopkinsmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- "Dr. Michael Carducci, A CLOSLER Look" - interview
CLOSLER (Johns Hopkins Miller Coulson Academy)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →closler.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine